NewAmsterdam Pharma (NAMS) Competitors $26.61 +1.90 (+7.69%) (As of 12/17/2024 05:46 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NAMS vs. ITCI, ROIV, ASND, RVMD, LNTH, NUVL, LEGN, BPMC, ELAN, and CYTKShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Legend Biotech Blueprint Medicines Elanco Animal Health Cytokinetics Intra-Cellular Therapies (NASDAQ:ITCI) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking. Which has better valuation & earnings, ITCI or NAMS? Intra-Cellular Therapies has higher revenue and earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$612.78M15.04-$139.67M-$0.87-99.95NewAmsterdam Pharma$33.59M73.18-$176.94MN/AN/A Does the media prefer ITCI or NAMS? In the previous week, NewAmsterdam Pharma had 19 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 26 mentions for NewAmsterdam Pharma and 7 mentions for Intra-Cellular Therapies. NewAmsterdam Pharma's average media sentiment score of 0.73 beat Intra-Cellular Therapies' score of 0.65 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 11 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ITCI or NAMS? Intra-Cellular Therapies presently has a consensus price target of $97.23, indicating a potential upside of 11.81%. NewAmsterdam Pharma has a consensus price target of $36.20, indicating a potential upside of 36.04%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ITCI or NAMS? Intra-Cellular Therapies received 500 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 67.84% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% NewAmsterdam PharmaOutperform Votes21100.00% Underperform VotesNo Votes Is ITCI or NAMS more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. NewAmsterdam Pharma's return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% NewAmsterdam Pharma N/A N/A N/A Do insiders & institutionals have more ownership in ITCI or NAMS? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, ITCI or NAMS? Intra-Cellular Therapies has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. SummaryNewAmsterdam Pharma beats Intra-Cellular Therapies on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.46B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E RatioN/A10.75135.1817.54Price / Sales73.18287.861,228.03140.34Price / CashN/A56.6540.6537.95Price / Book7.605.394.884.92Net Income-$176.94M$152.04M$118.97M$225.78M7 Day Performance4.07%-4.32%15.73%-1.58%1 Month Performance7.91%2.80%15.69%6.67%1 Year Performance145.03%17.30%34.73%22.48% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma2.5475 of 5 stars$26.61+7.7%$36.20+36.0%+147.8%$2.46B$33.59M0.0057Insider TradeHigh Trading VolumeITCIIntra-Cellular Therapies4.1678 of 5 stars$84.77+2.1%$97.23+14.7%+32.9%$8.99B$612.78M-95.91560ROIVRoivant Sciences2.667 of 5 stars$12.10+2.2%$17.93+48.2%+8.9%$8.81B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$136.32+5.0%$191.77+40.7%+16.0%$8.27B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.76-0.6%$63.67+42.2%+69.6%$7.53B$11.58M-12.54443Positive NewsLNTHLantheus4.4014 of 5 stars$94.94+2.1%$130.00+36.9%+21.9%$6.60B$1.50B15.42834Positive NewsNUVLNuvalent2.3475 of 5 stars$87.09+0.3%$112.60+29.3%+9.7%$6.19BN/A-25.0340Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.29-5.2%$81.54+144.9%-43.4%$6.08B$520.18M-36.971,800BPMCBlueprint Medicines2.9172 of 5 stars$95.51+2.5%$122.11+27.8%+9.7%$6.07B$434.42M-45.28640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.21+0.9%$16.75+37.2%-10.5%$6.04B$4.45B30.259,300CYTKCytokinetics3.9849 of 5 stars$49.12+1.0%$83.93+70.9%+32.5%$5.80B$3.22M-9.04250 Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Lantheus Alternatives Nuvalent Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NAMS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
